media – Page 6 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Trump calls for FDA price check with drug prices in ads

A particular proposal regarding displaying drug prices in TV ads flummoxed pharma marketers and ad agencies following the unveiling of the drug-pricing agenda by President Trump. Marketers have been hounded with the whys and hows of the proposal even as the administration remains firm on its implementation.
- Source: Ddu
- 87
- May 17, 2018
biopharmaceutical FDA pharma Policies
FDA Approves Qiagen’s PartoSure for Preterm Labor

On April 20, 2018, Qiagen announced the FDA approval of the novel test named PartoSureTM, used for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
- Source: Ddu
- 111
- May 17, 2018
medical device New Approvals preterm labor
New Sensor Detects Arsenic Contamination in One Min

Scientists from the Department of Chemistry at Imperial have developed a small, user-friendly, accurate and cost-effective sensor to test arsenic levels in drinking water within a minute. When a drop of water hits the test strip, it gives the arsenic level count digitally.
- Source: Ddu
- 109
- May 17, 2018
arsenic trioxide medical device New Approvals
AiCuris Partners with MPI for Antibiotic-Resistance Research

AiCuris along with Prof. Dr. Dr. H.C. Waldmann, Director of the Chemical Biology Department at MPI, will jointly investigate and optimize antibacterial or antiviral compounds, which could be developed into anti-infective drugs.
- Source: Ddu
- 153
- May 17, 2018
anti-infective antibiotic resistance Researches
The Kidney That Wanders – Floating Kidney Disease

It has always been believed that the internal organs stay in the same location in our bodies. But breaking news arose where a young woman in Michigan told doctors that she felt as if a ball was rolling inside her body whenever she moved. Upon being diagnosed, it was found that it was, in fact, not a ball but her right kidney. This condition was termed as ‘Floating Kidney’.
- Source: Ddu
- 239
- May 17, 2018
kidney Researches
New Blood Test for Liver Cancer Shows Promising Results

Liver cancer is the second most common cancer with a high mortality rate worldwide. According to WHO, liver cancer is the fifth most common cancer in men and seventh most common cancer in women. Treatment could be possible only if diagnosed at an early stage. Hence research studies were conducted worldwide to find the most accurate diagnostic tool to detect liver cancer.
- Source: Ddu
- 178
- May 17, 2018
cancer Researches
Attacking the common cold by unshielding its genome

The problem with the common cold is that it isn’t just one virus. It’s a family of viruses that evolve so quickly no one can ever be fully immune to the cold, and developing a vaccine that can tackle all of the variations of the virus is impossible. But what if there were one way to block the ability of all cold viruses from replicating—thereby fending off the sneezing, sore throat and general misery that they cause?
- Source: FierceBiotech
- 104
- May 16, 2018
common cold genome Researches
Feds join lawsuits claiming Insys used strip club visits, super-doses and more to boost Subsys sales

Prosecutors have already charged Insys founder John Kapoor and won guilty pleas from two characters in an ongoing kickbacks probe. Now, the Justice Department has escalated the case by joining in with whistleblowers who've detailed a stunning range of techniques the company allegedly used to push its powerful opioid painkiller.
- Source: FiercePharma
- 167
- May 16, 2018
Company Insight lawsuit pharma
FDA approved Pfizer biosimilar Epogen/Procrits

The FDA granted approval to Pfizer for Retacrit (epoetin alfa-epbx), which is used for the treatment of anemia, biosimilar of Amgen, a drug which generated sales closely $ 1.8 billion in the U.S market last year for Amgen and Johnson & Johnson partners. Retacrit also received the go-ahead to be used in RBC transfusions by U.S health regulators.
- Source: Ddu
- 85
- May 16, 2018
anemia New Approvals Pfizer pharma
U.S. healthcare to be disrupted through a low-cost health network

As America’s population ages, a 4 billion USD opportunity is being foreseen by Thomas DeRosa for changing the U.S. health infrastructure through instituting a low-cost healthcare network and disrupting conventional healthcare practices.
- Source: Ddu
- 130
- May 16, 2018
healthcare Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

Exhibitions & Activitiesmore

Market Reportsmore

China’s Import and Export Market Report of Diabetes Drugs

May 4, 2018
China’s Import and Export Market Report of Vitamins

April 11, 2018
China’s Import and Export Market Report of Contraceptive Drugs

March 16, 2018
Ddu College — China’s Import and Export Report of Peptic Ulcer Drugs

January 25, 2018
China’s Import and Export Report of External Use Otology Drugs

January 12, 2018

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.